Pharvaris (NASDAQ:PHVS) Insider Wim Souverijns Sells 20,000 Shares of Stock

Pharvaris N.V. (NASDAQ:PHVS) insider Wim Souverijns sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, September 14th. The shares were sold at an average price of $39.31, for a total transaction of $786,200.00. Following the completion of the transaction, the insider owned 45,111 shares in the company, valued at $1,773,313.41. The trade was a 30.72% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Wim Souverijns also recently made the following trade(s):

• On Tuesday, September 15th, Wim Souverijns sold 6,090 shares of Pharvaris stock. The shares were sold at an average price of $38.99, for a total transaction of $237,449.10.

Pharvaris Stock Down 1.3%

PHVS opened at $37.55 on Thursday. Pharvaris N.V. has a 52-week low of $20.65 and a 52-week high of $43.25. The company has a 50 day moving average of $35.31 and a two-hundred day moving average of $31.63. The company has a market cap of $2.46 billion, a P/E ratio of -12.31 and a beta of -2.33.

Pharvaris (NASDAQ:PHVS) last issued its earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06). Research analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have commented on PHVS shares. Leerink Partners boosted their price objective on Pharvaris from $50.00 to $65.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 9th. New Street Research set a $60.00 target price on Pharvaris in a research note on Friday, August 14th. Wells Fargo & Company raised their target price on Pharvaris from $55.00 to $65.00 and gave the company an “overweight” rating in a report on Wednesday, September 9th. Oppenheimer reissued an “outperform” rating and set a $75.00 price target on shares of Pharvaris in a research report on Tuesday, September 8th. Finally, Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a report on Saturday, July 18th. Thirteen investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $59.87.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently added to or reduced their stakes in the company. Quantbot Technologies LP purchased a new position in Pharvaris in the 2nd quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in shares of Pharvaris during the second quarter worth about $93,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Pharvaris during the fourth quarter worth about $139,000. Public Employees Retirement System of Ohio acquired a new position in shares of Pharvaris in the second quarter worth about $196,000. Finally, Algert Global LLC acquired a new position in shares of Pharvaris in the second quarter worth about $238,000.

More Pharvaris News

Here are the key news stories impacting Pharvaris this week:

• Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema attacks by 83%. The result strengthens the case for the company’s lead drug and supports planned regulatory submissions in 2027. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
• Positive Sentiment: Analyst expectations remain favorable. The reported consensus price target rose 20.08% to $59.77, while recent targets include $62 from RBC and $65 from Wells Fargo and Leerink Partners. The broader analyst consensus is “Moderate Buy.” Pharvaris Consensus Price Target Raised
• Positive Sentiment: Recent institutional activity has been supportive, including a new BlackRock position and larger holdings from Alyeska Investment Group and Seven Fleet Capital, suggesting increased professional-investor interest.
• Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference. The event provided management with an opportunity to discuss deucrictibant and its regulatory strategy, but the supplied transcript does not identify a separate new announcement. Pharvaris Morgan Stanley Conference Transcript
• Negative Sentiment: Insider selling is weighing on sentiment. Insider Wim Souverijns sold 26,090 shares for approximately $1.02 million across September 14–15, while CEO Berndt Modig sold 2,291 shares worth about $90,265. President Peng Lu also sold 15,000 shares for roughly $602,000 to cover tax withholding related to vested equity awards. Anne Lesage separately sold 30,000 shares for approximately $1.15 million. Although some sales were tax-related and insiders retain significant holdings, the volume of selling can raise concerns about near-term supply and insider confidence. Pharvaris Insider Selling

Pharvaris Company Profile

Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.

Pharvaris’ lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.